Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis-Reference-Cited by-同舟云学术

Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis

Published:2022-06-21 Issue:4 Volume:15 Page:818-821
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Azami Tetsushi,Takano Yuichi,Noda Jun,Yamawaki Masataka,Yoshida Erika,Niiya Fumitaka,Maruoka Naotaka,Ogawa Takafumi,Ichikawa Wataru,Nagahama Masatsugu

Funder

Taiho Pharmaceutical

Chugai Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12328-022-01651-3.pdf

Reference8 articles.

1. Nabeshima S, Yamasaki M, Matsumoto N, et al. Atezolizumab-induced sclerosing cholangitis in a patient with lung cancer: a case report. Cancer Treat Res Commun. 2021;26: 100270.

2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.

3. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.

4. Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353–65.

5. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965–73.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atezolizumab;Reactions Weekly;2022-08-27